• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Imaging and Intervention

Shorter-duration whole breast irradiation may be underutilized

byKhang DinhandDavid Wang
December 13, 2014
in Imaging and Intervention, Obstetrics, Oncology, Surgery
Reading Time: 3 mins read
Share on FacebookShare on Twitter

1. Analysis of health care claims data demonstrated significantly reduced hypofractionated whole breast irradiation (WBI) utilization in the United States compared to Canada and the United Kingdom.

2. Hypofractionated WBI was associated with significantly decreased total health care expenditure compared to conventional WBI.

Evidence Rating Level: 3 (Average)

Study Rundown: The current standard of care of early-stage breast cancer (ESBC) is breast conservation surgery followed by whole-breast irradiation (WBI).  Recently, randomized controlled trials completed in Canada and the United Kingdom demonstrated that a shorter, 3-5 week regimen of radiation was equivalent to the conventional 5-7 weeks of WBI.  In 2011, the American Society for Radiation Oncology (ASTRO) recommended the use of this shorter-course, or hypofractionated WBI for women with ESBC 50 or older who meet criteria and permitted hypofractionated WBI for women 50 or younger with ESBC. The purpose of this study is to determine the uptake of hypofractionated WBI since this recommendation. Claims and eligibility data from 14 commercial health plans in the United States were retrospectively reviewed for use of hypofractionated versus conventional WBI in women with ESBC as well as total costs expenditures for these two modalities. At the conclusion of the study, the authors demonstrated that the use of the hypofractionated regimen increased from 10.6% in 2008 to 34.5% in 2013. However, the rate of uptake was significantly less compared to the rate of hypofractionated WBI use in both Canada and the United Kingdom, suggesting that hypofractionated WBI may be underutilized in the United States. Furthermore, hypofractionated WBI was associated with a significant reduction in total health care expenditure for patients of either age group compared to conventional WBI. The main limitation of this study was the retrospective methodology, which may be subject to misclassification error and bias. Future prospective trials on patterns of hypofractionated WBI use are required to validate the uptake trend of this hypofractionated WBI.

Click to read the study in JAMA

Relevant Reading: Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

RELATED REPORTS

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

2 Minute Medicine Rewind August 10, 2026

In-Depth [retrospective cohort]: This study retrospectively analyzed the administrative claims data from 14 commercial health care plans, representing 9.2 million US women, for use of hypofractionated versus conventional WBI in patients with ESBC from 2008 to 2013. This dataset included data from Medicare Advantage enrollees as well as commercial payers. Overall, the study cohort included 8924 ESBC patients met all ASTRO criteria to endorse hypofractionation as well as 6719 ESBC patients considered to be in a “hypofractionation-permitted” cohort.  In the hypofractionation-endorsed cohort, hypofractionation rates increased from 10.6% (95% CI: 8.8%-12.5%) in 2008 to 34.5% (95% CI: 32.2%-36.8%) in 2014. In the hypofractionation-permitted cohort, rates increased from 8.1% (95% CI: 6.0%-10.2%) in 2008 to 21.2% (95% CI: 18.9%-23.6%) in 2014. Total health-related expenditures were $2894 lower for patients receiving hypofractionated WBI compared to conventional WBI (95% CI: $1610-$4234; P<0.001) in the endorsed cohort while that difference was $8585 (95% CI: $5316-$12,017; P<0.001) in the permitted cohort. The percentage of patients that received conventional WBI (>30 fractions) was significantly increased in the United States compared to Ontario, Canada (52.7% vs 6.3%).

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: Breast Cancerhypofractionated whole breast irradiation
Previous Post

Blood cell clones with acquired mutations linked with increased risk of blood cancers

Next Post

Injectable loaded microparticle scaffolds improve vaccine responses in mice [PreClinical]

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026
Next Post
Injectable loaded microparticle scaffolds improve vaccine responses in mice [PreClinical]

Injectable loaded microparticle scaffolds improve vaccine responses in mice [PreClinical]

Colonic byproduct may decrease long-term weight gain

Colonic byproduct may decrease long-term weight gain

Medical comorbidities associated with poor semen quality

Medical comorbidities associated with poor semen quality

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Brepocitinib becomes first oral therapy approved for adult dermatomyositis
  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.